Most of these cytokines and chemokines (CCL2, IL-1β, IL-6, IL-23, TNF-α, IL-17F) were reduced in IBD patients on ARB therapy, especially for the active patients (Fig. 7). The gene discussed is IL23A; the disease is inflammatory bowel disease.